

Financial Officer for Sara Lee Meats, and Vice President, Finance and Chief Financial Officer for PYA/Monarch, Inc. From 1985 to 1993, Ms. Bellantoni was with Emerson Electric Company, as Vice President, Finance and Chief Financial Officer for their Automatic Switch Division and Vice President, Far East and Vice President, Finance and Chief Financial Officer for the Branson Ultrasonics Corporation.

On January 10, 2006, the Company entered into an Employment Agreement with Ms. Bellantoni. The following is a summary of the material terms of the agreement.

Term

The employment agreement provides for a term of employment with the Company through January 10, 2007, with an automatic extension of the term of employment for consecutive one year periods unless the Company or Ms. Bellantoni provides notice that it or she elects not to extend the term.

Compensation and Benefits

The employment agreement provides that Ms. Bellantoni's base salary will be \$300,000. In addition, Ms. Bellantoni will have a target bonus opportunity of 40% of her base salary, based upon the satisfaction of certain performance objectives as determined by the Compensation Committee of the Board of Directors of the Company, in its sole discretion. The bonus will be paid part in cash and part in restricted equity securities. Ms. Bellantoni is also eligible to participate in the Company's employee benefit plans, stock-based plans and any other plans and benefits covering executives of the Company.

Ms. Bellantoni will be reimbursed for (i) reasonable expenses for a temporary apartment and rental car for ninety days, (ii) up to \$25,000 of expenses incurred in relocating her principal residence and (iii) up to \$75,000 of real estate brokerage and legal fees arising from the purchase of a principal residence within commuting distance of the Company's headquarters. Ms. Bellantoni will be required to reimburse the Company for all of the above amounts if she terminates her employment with the Company during the initial term of the employment agreement and for half of the above amounts if the agreement is renewed and she terminates her employment with the Company between January 11, 2007 and January 10, 2008.

Equity Grant

On January 10, 2006, pursuant to the terms of her employment agreement, Ms. Bellantoni received an award of 10,000 shares of the Company's common stock, subject to restrictions and forfeiture, under the Company's 2003 Equity Incentive Plan. The award agreement provides that shares of common stock will be issued to Ms. Bellantoni on January 10, 2009 if the Company sales in 2006, 2007 or 2008 are greater than sales in 2005. The shares will be issued earlier if the Company experiences a change in control.

Severance Payments

If Ms. Bellantoni's employment with the Company is terminated by the Company for a reason other than death, disability or cause or Ms. Bellantoni terminates her employment with the Company for good reason, the Company will pay to her a lump sum cash severance amount equal to her annual base salary as of her last day of active employment. In addition, the Company will continue to maintain and provide to Ms. Bellantoni continued participation in all group insurance, life insurance, health and accident, disability and other employee benefit plans of the Company in which she would have been entitled to participate had her employment not terminated, at no cost, for a period ending on the earlier to occur of (i) the first anniversary of her last day of employment, (ii) the date she is employed on a full-time basis by another employer, or (iii) her death, provided the continued participation in such plan is not prohibited by the terms of the plan or for legal reasons. The Company will also reimburse Ms. Bellantoni for any expenses that she incurred in relocating her principal residence for which she is entitled to be reimbursed, including reimbursement for income taxes that she incurs, if any, on any amounts reimbursed to her.

Ms. Bellantoni's employment agreement provides that, instead of the foregoing severance benefits, if within 12 months of a change in control of the Company, her employment with the Company is terminated by the Company for a reason other than death, disability or cause or she terminates employment with the Company for good reason, the Company will pay to her a lump sum cash payment equal to 2.99 times the sum of her annual base salary as of her last day of active employment and target bonus. In addition, the Company will continue to maintain and provide to Ms. Bellantoni continued participation in all group insurance, life insurance, health and accident, disability and other employee benefit plans of the Company in which she would have been entitled to participate in had her employment not terminated, at no cost, for a period ending on the earlier to occur of (i) the first anniversary of her last day of employment or (ii) her death, provided the continued participation in such plan is not prohibited by the terms of the plan or for legal reasons. All reasonable fees and expenses incurred by Ms. Bellantoni as a result of her termination of employment will be paid by the Company.

The above severance benefits are conditioned on Ms. Bellantoni and the Company executing a release.

If any payment, coverage or benefit provided to Ms. Bellantoni is subject to the excise tax under Section 4999 of the Internal Revenue Code of 1986, as amended (the "Code"), she will receive a "gross-up" payment so she would be in the same net after-tax position she would have been in had Sections 280G and 4999 not been part of the Code.

Restrictive Covenants

Ms. Bellantoni's employment agreement provides that during the term of this agreement, and for the one year period after Ms. Bellantoni's termination of employment with the Company, Ms. Bellantoni will be subject to certain covenants not to compete against the Company.

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.

(c) Exhibits.

Exhibit Number	Description of Exhibit
-----	-----
99.1	Press release issued January 10, 2006

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

INTEGRA LIFESCIENCES HOLDINGS CORPORATION

Date: January 17, 2006

By: /s/ Stuart M. Essig

Stuart M. Essig
President and Chief Executive Officer

Exhibit Index

Exhibit Number	Description of Exhibit
-----	-----
99.1	Press release issued January 10, 2006

Contacts:

Integra LifeSciences Holdings Corporation

John B. Henneman, III
Executive Vice President
Chief Administrative Officer
(609) 936-2481
jhenneman@Integra-LS.com

Maria Platsis
Senior Director of Corporate Development
and Investor Relations
(609) 936-2333
mplatsis@Integra-LS.com

Integra LifeSciences Names Maureen Bellantoni
Chief Financial Officer

Plainsboro, New Jersey / January 10, 2006 / -- Integra LifeSciences Holdings Corporation (NASDAQ: IART) announced today that Maureen Blanchfield Bellantoni will join the Company as Executive Vice President and Chief Financial Officer, effective immediately. Ms. Bellantoni joins Integra with more than twenty years experience in finance, accounting and operations.

"We are delighted that Maureen has agreed to join Integra," said Stuart M. Essig, Integra's President and Chief Executive Officer, who is speaking at the 24th Annual JPMorgan Healthcare Conference. "Maureen will be focusing on all aspects of our financial organization. I look forward to working closely with Maureen as together we continue to build Integra through internal development and strategic acquisitions."

"Maureen brings with her a diverse background of experience which we expect to significantly strengthen our management team," said Keith Bradley, Chairman of Integra's Audit Committee. "With her strong financial and operations background, she will be a valuable asset to our Company as we continue to pursue our expansion strategy."

"Integra's commitment to growth and profitability in the medical technology industry is extremely impressive," said Ms. Bellantoni. "I am pleased to have the opportunity to make a contribution to Integra's success at such an important stage of its development."

David Holtz, currently Senior Vice President, Finance, will maintain his role of principal accounting officer as well as assume responsibility for worldwide shared services and planning and will report to Ms. Bellantoni. In this expanded role, Mr. Holtz will utilize his experience in planning and reporting to unify this critical worldwide function and to ensure that Integra's standards are directly aligned and support the Company's strategy.

Ms. Bellantoni has extensive experience in both finance and operations. She most recently served as Senior Vice President and Chief Financial Officer of CP Kelco, a global leader in the hydrocolloids market from 2003 through its sale to J.M. Huber. The business was owned by Lehman Brothers and J.M. Huber. From 2000 to 2002 Maureen served as Chief Financial Officer North America and Senior Vice President of Finance of Burger King where she managed the worldwide finance organization enabling the company to execute its business turnaround plan and its separation from parent company Diageo, plc. During 1999 to 2000 she served as Executive Vice President Finance for Rohn Industries Inc., a publicly traded telecommunications company.

From 1993 to 1998 she served at Sara Lee Corporation as President and Chief Operating Officer for their Bil Mar Foods division, Vice President, Finance and Chief Financial Officer for Sara Lee Meats, and Vice President, Finance and Chief Financial Officer for PYA/Monarch, Inc. At Sara Lee, Ms. Bellantoni oversaw division CFOs throughout the United States, Mexico and Europe, and was responsible for implementing rapid growth for her divisions, including designing aggressive growth plans and coordinating worldwide business and operational strategies.

From 1985 to 1993 Ms. Bellantoni was with Emerson Electric Company, as Vice President, Finance and Chief Financial Officer for their Automatic Switch Division and Vice President, Far East and Vice President, Finance and Chief Financial Officer for the Branson Ultrasonics Corporation.

From 1996 to 2000 she served as a Member of the Board of Directors, Audit Committee, and Compensation Committee of Michael Foods, Inc. Ms. Bellantoni received a Bachelor of Science Degree from the University of Bridgeport and a

Master of Business Administration from the University of Connecticut.

Integra LifeSciences Holdings Corporation is a diversified medical technology company that develops, manufactures, and markets medical devices for use in a variety of applications. The primary applications for our products are neurosurgery, reconstructive surgery and general surgery. Integra is a leader in applying the principles of biotechnology to medical devices that improve patients' quality of life. Our corporate headquarters are in Plainsboro, New Jersey, and we have manufacturing and research facilities located throughout the world. We have approximately 1,300 employees. Please visit our website at (<http://www.Integra-LS.com>).

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. The economic, competitive, governmental, technological and other factors identified under the heading "Factors That May Affect Our Future Performance" included in the Business section of Integra's Annual Report on Form 10-K for the year ended December 31, 2004 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.

Source: Integra LifeSciences Holdings Corporation